US Stem Cell Scientist Punished for Fraud
By Michael Cook,
BioEdge
| 09. 07. 2012
Stem cell research fraud continues, though not as spectacularly as in the lab of disgraced South Korean Hwang Woo-suk. A Harvard University researcher, Shane Mayack, was recently
disciplined by the Office of Research Integrity (ORI) of the Department of Health and Human Services for using images from other publications as her own. Dr Mayack has acknowledged her responsibility for misconduct, which led to retractions of two papers in the prestigious journals Nature and Blood.
Last year Dr Mayack discussed the scandal in an essay posted on the blog
Retraction Watch. She admitted that she had made “egregious” mistakes, but she blamed a “dysfunctional” system as well:
“… the mistakes made were serious, even egregious. I take responsibility for these mistakes, and I understand that there are and should be some degree of consequence. I am a professional, well-trained individual and more should be expected of me.
“That being said, more should be expected of all of us — the system as a whole — shouldn’t it? Errors in scientific data that make their way into publications do so...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...